We raise '25e-'27e adj. EBITA by 10-1% on higher margins Low renegotiation risk 2025 and growth upsi...
Redeye is not entirely surprised to see that Absolent has experienced significant headwinds in Q1.
Redeye provides an initial comment on the Q1 2025 report from Serstech.
Volvo delivered a mixed report, with EBIT 12% below Infront consensus.
Adj. EBITA +12% vs. cons, +39% vs. ABGSCe Better margins and guidance to improve conviction in margi...
Redeye comments on Thunderful Group ahead of its Q1 results, due on 15 May.
On April 22nd, Genetic Analysis AS (“Genetic Analysis” or the “Company”) announced that the Company ...
Two divestments and one acquisition announced Net effect: EBITA +4%, margins to increase from 9.
This friday, between 14.00 - 16.00, NextCell Pharma invites investors, analysts, and media to an inv...
Under de senaste sex månaderna har bolaget genomfört tre exits; Blackbuck, Gringo och Juspay, vilket...
We cut '25e-'27e adj. EBITA by 13-1% Gross profit per consultant at normal levels in '26e '25e EV/EB...
We trim '25e-'27e ARR by 1-3% on continued macro weakness Volume-based revenue growth could pick up ...
FX-driven estimate changes Direct tariff impact likely minor NTM EV/EBIT of just below 7x What to l...
Q1e sales flat q-o-q, slight margin improvement to 5.
Enersense could release new financial targets as a pure service company on 28 April.
